Catalent in the news

Catalent introduces a ten-month gene-to-drug substance program for complex biologics in the US, leveraging its GPEx Lightning cell line to expedite development from gene sequence to drug substance.

Catalent introduced a new accelerated program in the U.S. to develop complex biologics from gene sequence to drug substance in 10 months.

Catalent launched a U.S. program to accelerate complex biologic development from gene to drug substance in 10 months.

Catalent introduces a new accelerated program in the US to fast-track complex biologics from gene sequence to drug substance in 10 months.

ALK-Abelló expanded its manufacturing partnership with Catalent, increasing capacity and technology access, despite recent share price pressure and valuation debates.

ALK is expanding its manufacturing partnership with Catalent, investing DKK 500 million to increase tablet capacity by 40% to 1.1 billion tablets annually for allergy treatments, despite Catalent being a privately owned company.

ALK is paying Catalent $76 million to increase production capacity and secure long-term technology access.

ALK expanded its manufacturing partnership with Catalent, increasing tablet production capacity to 1.1 billion annually by 2030 and investing DKK 500 million.

ALK has expanded its partnership with Catalent for tablet supply.

ALK expanded its manufacturing agreement with Catalent, investing $76 million to secure long-term access to Zydis technology and increase tablet production capacity.

ALK expanded its contract manufacturing partnership with Catalent, increasing tablet production capacity to 1.1 billion annually and investing DKK 500 million over three years.

Catalent secured a USD 4.7 billion refinancing package to fund future investments and support continued growth, with a focus on expanding manufacturing capacity and advancing technology.

Catalent's stock is trading near its yearly low, but analysts expect significant revenue and earnings growth in the upcoming quarter.

Catalent stock gained after the FDA cleared a key manufacturing site, easing compliance concerns, despite recent quarterly figures showing revenue growth but declining profit margins.

Catalent's stock is holding steady as investors await its next earnings report and guidance, with focus on revenue, margins, and balance sheet strength.

Catalent secured a $4.1 billion debt refinancing to expand its manufacturing capacity for biologics and oral drugs, driven by strong customer demand and onshoring trends.

Catalent is implementing a custom AI solution on Azure to enhance its quality management system, focusing on deviation management and root-cause analysis.

Catalent completed a $4.1 billion debt refinancing, expected to reduce its annual interest expense by $100 million and improve its financial liquidity.

Scholar Rock removed Catalent's Indiana facility from its FDA application for a muscle weakness drug due to compliance issues, proceeding with a different facility for approval.

Catalent successfully refinanced its debt, securing a new $4.1 billion term loan and $600 million revolving credit facility, which is expected to cut annual interest expenses by $100 million and improve its financial flexibility.